With brand new CBD regulations coming into force this year and an array of products hitting the market, Speciality Food put CBD food and drink under the microscope.
Now that the UK regulates CBD as a natural supplement, industry groups are calling on the government to reform contradictory hemp laws
Consumer demand for CBD products has soared during lockdown, according to the Association for the Cannabinoid Industry (ACI), which estimates the sector will generate £690 million in annual sales this year, above a previous forecast of £526 million.
“We were expecting it to grow,” Steve Moore, co-founder and strategic counsel to the CMC and ACI, tells NutritionInsight. “It was always likely that when levels of stress and anxiety would rise with the various lockdowns we’ve had here in the UK, the pandemic would increase demand.”
Sky News reports on our new report and how sales of consumer cannabis products have undergone an “accidental” boom during the pandemic.
Research from two industry pressure groups reveals the UK cannabinoid (CBD) industry was worth £690 million in the 12 months to the end of April – up almost a third year on year.
The UK CBD market could generate £690 million (€800 million) in 2021 sales. More government intervention and investment is needed “to ensure that the UK optimizes ‘Britain’s quiet cannabis revolution’,” ACI’s report urges.
The sector is now estimated to generate £690 million in annual sales for 2021. This figure surpasses predictions made in the seminal market sizing study undertaken by the CMC in 2019 which estimated the market would be worth £526 million in 2021.
The report argues that the market represents a key growth sector for the UK and it is time for the government to adopt a proactive strategy to seize opportunities in the cannabinoids sector. It makes 20 recommendations to stimulate post-Covid economic growth.
The UK CBD sector is predicted to generate £690 million in annual sales in 2021, according to a new report from two leading industry bodies.
The report from the Centre for Medicinal Cannabis (CMC) and the Association for the Cannabinoid Industry (ACI) was published this morning.
CBD brands have had more than a year to sort out their novel food applications, but only three have made the grade so far. The Grocer investigates what’s going on?
As Novel Food regulations for CBD products come into effect, Jersey Hemp speaks to ACI’s External Affairs director Shomi Malik about the importance of robust, relevant scientific data in moving the industry into the mainstream.
The Association for the Cannabinoid Industry (ACI) has publicly refuted the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
Results from a major US trial over 800 people over the past seven months found CBD use has zero impact on the liver. ACI member, Columbia Care, Charlotte’s Web and 10 other US companies provided around $1m for a trial which started last summer – and now appears to have answered the CBD safety question.
CBD industry experts have put together a detailed safety review of THC recommending clear policy recommendations to cut market confusion reports NutraIngredients
Canex cover news of the release of our detailed safety review report on THC.
As outlined in ACI’s report “Health Guidance Levels for THC in CBD products,” the industry group recommend that the UK Home Office enacts a cap of 0.021 mg/kg of THC (and other cannabinol derivatives) per day. This limit would be equivalent to permitting 0.03 percent THC per the recommended 70 mg daily intake of CBD.
ACI member Treehouse Biotech has submitted a Novel Foods application to UK authorities for its Cannabidiol (CBD)-based ingredients in a move that signals the US firm’s intent to capture a slice of the UK’s burgeoning CBD market.
Pharmacy Business Magazine reports that the FSA updated the criteria for CBD products which can remain on sale from 1 April 2021. Previously, only products which were on sale at the time of the FSA’s announcement (13 February 2020) and were linked to an application which had been validated by 31 March 2021 were to be included.
Last February, the Food Standards Agency (FSA) announced that all CBD businesses operating in England and Wales must have a novel foods application “validated” by March 31, 2021, or risk having their CBD oils, drinks, and treats “taken off the shelves.” Now, with just over two weeks left until the deadline, the FSA has clarified that all applications just have to be “submitted” by March 31, 2021.
Coverage from the US publication Hemp Grower on the requirement for novel foods applications to sell CBD products in the UK.
[Cannavist] The Food Standards Agency (FSA) has updated its criteria for CBD products to remain on sale after April 1
Previously, only products that were on sale on February 13, 2020 and linked to an application that had been validated by the March 31, 2021 deadline could continue to be sold.
The criteria for CBD products which can remain on sale from 1 April 2021 has been updated by the Food Standards Agency (FSA).
The FSA has backtracked on its initial expectation for companies to make their novel foods applications at least five weeks in advance of the deadline and confirmed that it will accept applications up until March 31st, after receiving a large number of last minute dossiers.
Many UK CBD brands have been misled on how to prepare for the looming novel foods deadline meaning there is less than one month for some to pull together potentially impossible amounts of data, an industry expert has warned.
Writing for BusinessCann, Dr Paul Duffy, Toxicology Associate, at the ACI, elaborates on our Novel Food applications and the significance of these development for the the CBD industry
[Pharmacy Business Magazine] Industry body submits CBD novel food application for validation by Food Standards Agency
The Association for the Cannabinoid Industry (ACI) has submitted its novel food application to the FSA on behalf of CBD manufacturers. This marks a pivotal milestone for the ACI as it met the compliance deadline set by the UK’s Food Standards Agency (FSA), the association said in an update on Tuesday (Feb 16).
Following the submission of its novel food application, New Food gets exclusive insight from three experts integral to the study…
The Association for the Cannabinoid Industry (ACI) has submitted its novel food application on behalf of the members of its CBD Safety Study Consortium. The ACI has called this a pivotal milestone as its members have been working together to meet the compliance deadline set by the UK’s Food Standards Agency (FSA).
Despite the UK’s exit from the European Union and the end of the ‘transition period’ at the beginning of this year, it appears that the European Commission’s ruling on the novel status of CBD will stand. This means that all manufacturers and producers of CBD products in the UK will still be expected to have completed a Novel Foods application by the deadline later this year.
[Informa Pharma Insights] UK CBD Industry Embraces Trading Standards Partnership As Compliance Deadline Looms
UK CBD industry association, the ACI, joins others in forming partnerships with local authorities responsible for enforcing the new rules, which require all CBD food supplements on the market to hold a validated novel food application with the FSA.
[Food Navigator] ‘This will boost consumer confidence that they can trust these products’: CBD industry predicts sales lift as deadline for novel food applications approaches
With the UK deadline for Novel Food applications for CBD products approaching on March 31, industry body the Association for the Cannabinoid Industry (ACI) has announced a partnership with Trading Standards to ensure a smooth transition.
The Association for the Cannabinoid Industry (ACI) has announced on Tuesday (Feb 2) that it is the first UK cannabis industry association to formalise a partnership with Trading Standards. The latest agreement was approved by the Secretary of State last week.
After cumulatively spending tens of millions of pounds on Novel Food compliance many UK CBD companies may be left feeling frustrated come the end of March deadline.
On April 1. the much-touted and controversial Novel Food rules come into place for businesses in the CBD supply chain.
Food Standards Scotland (FSS) has sought to clarify its position concerning the sale of CBD-related products, in a stance that clashes with the opinion set out by the UK Food Standards Authority (FSA).
NutritionInsight provides an overview of the various business developments over the holiday period and includes the clarification ACI received from FSS on their stance on CBD.
[Food Navigator] ‘A Christmas wish come true’: CBD industry celebrates as EC resumes Novel Food applications
More good news for the CBD industry. The European Commission has abandoned its plans to classify non-synthetic CBD a narcotic and resumed Novel Food applications for edible CBD products.
The move came after the European Court of Justice ruled that CBD is not a narcotic drug as it “does not appear to have any psychotropic effect or any harmful effect on human health”.
Landmark decisions by the United Nations (UN) and European Commission around the classification of cannabis and cannabidiol has opened the door to manufacturers of CBD-based products, as the two international bodies moved to relax legislation around the substance last week.
ConfectioneryNews looks at some of the benefits, and also the issues, of using dietary and medicinal ingredients in sweets. The use of confectionery products to carry over-the-counter (OTC) medications or dietary supplements is increasing as consumers realise that hard candy, jellies or fruit products are one of the quickest ways of getting nutrients into the body. The demand for functional jellies continues to grow with herbal extracts, cannabinoids and vitamins proving a good fit with the mainstream candy sector.
The ruling is a boost to the CBD sector in Europe after the EU decision to potentially classify CBD as a narcotic. The court stated that: ‘A Member State may not prohibit the marketing of cannabidiol (CBD) lawfully produced in another Member State when it is extracted from the Cannabis sativa plant in its entirety and not solely from its fibre and seeds.’ And that: ‘the provisions on the free movement of goods within the European Union (Articles 34 and 36 TFEU) are applicable, since the CBD at issue in the main proceedings cannot be regarded as a ‘narcotic drug’.’
The CBD sector is notoriously confusing. Here, the Association for the Cannabinoid Industry offers sound advice for staying ahead and remaining compliant.
[Food Navigator] ‘A breakthrough for the market’: Europe’s highest court rules CBD is not a narcotic
Europe’s CBD market is optimistic a ruling from the EU’s highest court not to classify the ingredient a narcotic – going against the European Commission’s shock preliminary view in July – will pave the way for Novel Food applications for CBD products to re-start.
The Court of Justice of the European Union ruled CBD is not a narcotic drug as it “does not appear to have any psychotropic effect or any harmful effect on human health”.